Search

Your search keyword '"Hutchings, Martin"' showing total 23 results
Start Over Author "Hutchings, Martin" Publication Year Range This year
23 results on '"Hutchings, Martin"'

1. Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials

Author

Juul, Sidsel J., Rossetti, Sára, Kicinski, Michal, van der Kaaij, Marleen A. E., Giusti, Francesco, Meijnders, Paul, Aleman, Berthe M. P., Raemaekers, John M. M., Kluin-Nelemans, Hanneke C., Spina, Michele, Fermé, Christophe, Renaud, Loïc, Casasnovas, Olivier, Stamatoullas, Aspasia, André, Marc, Le Bras, Fabien, Plattel, Wouter J., Henry-Amar, Michel, Hutchings, Martin, and Maraldo, Maja V.

Published
2024
Full Text
View/download PDF

2. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Author

Linton, Kim M, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, and Vose, Julie M

Published
2024
Full Text
View/download PDF

3. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Author

Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D, Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, and Hoster, Eva

Published
2024
Full Text
View/download PDF

5. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Author

Karimi, Yasmin, primary, Thieblemont, Catherine, additional, Ghesquieres, Hervé, additional, Cheah, Chan Y, additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Jurczak, Wojciech, additional, Linton, Kim M., additional, Hutchings, Martin, additional, Phillips, Tycel Jovelle, additional, Farooq, Umar, additional, Kim, Won Seog, additional, Dinh, Minh H, additional, Ghosh, Jagannath, additional, Pallai, Rajash, additional, Wielgos-Bonvallet, Monica, additional, Eskelund, Christian, additional, Lugtenburg, Pieternella, additional, and Vose, Julie, additional

Published
2024
Full Text
View/download PDF

6. Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.

Author

Bartlett, Nancy L., primary, Dickinson, Michael, additional, Hutchings, Martin, additional, Carlo-Stella, Carmelo, additional, Wu, Shang-Ju, additional, Leppä, Sirpa, additional, Trneny, Marek, additional, Corradini, Paolo, additional, Offner, Fritz, additional, Mulvihill, Estefania, additional, Bottos, Alessia, additional, Chohan, Saibah, additional, Baumlin, Pauline, additional, Relf, James, additional, Lundberg, Linda, additional, and Bachy, Emmanuel, additional

Published
2024
Full Text
View/download PDF

7. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.

Author

Vandtved, Julie Haugaard, Øvlisen, Andreas Kiesbye, Baech, Joachim, Weinrich, Ulla Møller, Severinsen, Marianne Tang, Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Glimelius, Ingrid, Kamper, Peter, Hutchings, Martin, Specht, Lena, Dahl‐Sørensen, Rasmus, Christensen, Jacob Haaber, and El‐Galaly, Tarec C.

Subjects
OBSTRUCTIVE lung diseases, INTERSTITIAL lung diseases, PULMONARY fibrosis, CHRONIC obstructive pulmonary disease, LUNG diseases
Abstract

Summary: Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin‐containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population‐based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age‐ and sex‐matched comparators from the background population. Median follow‐up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30–3.68]), with a 10‐year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35–26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43–2.76]), with a 10‐year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43–1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B‐symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work‐up of pulmonary symptoms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Reply to T. Vassilakopoulos et al

Author

Federico, Massimo, primary, Plattel, Wouter, additional, Hutchings, Martin, additional, Stepanishyna, Yana, additional, Fortpied, Catherine, additional, and André, Marc, additional

Published
2024
Full Text
View/download PDF

9. Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma

Author

Rask Kragh Jørgensen, Rasmus, primary, Bergström, Fanny, additional, Eloranta, Sandra, additional, Tang Severinsen, Marianne, additional, Bjøro Smeland, Knut, additional, Fosså, Alexander, additional, Haaber Christensen, Jacob, additional, Hutchings, Martin, additional, Bo Dahl-Sørensen, Rasmus, additional, Kamper, Peter, additional, Glimelius, Ingrid, additional, E Smedby, Karin, additional, K Parsons, Susan, additional, Mae Rodday, Angie, additional, J Maurer, Matthew, additional, M Evens, Andrew, additional, C El-Galaly, Tarec, additional, and Hjort Jakobsen, Lasse, additional

Published
2024
Full Text
View/download PDF

11. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim M, primary, Jurczak, Wojciech, additional, Lugtenburg, Pieternella J., additional, Gyan, Emmanuel, additional, Sureda, Anna, additional, Christensen, Jacob Haaber, additional, Hess, Brian, additional, Tilly, Herve, additional, Cordoba, Raul, additional, Lewis, David John, additional, Okada, Craig, additional, Hutchings, Martin, additional, Clausen, Michael Roost, additional, Vitolo, Umberto, additional, Cochrane, Tara, additional, Leppä, Sirpa, additional, Chamuleau, Martine E.D., additional, Conlon, Rebekah, additional, Favaro, Elena, additional, Favaro, Diana, additional, Altıntaş, Işıl, additional, Liu, Yan, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

12. Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma

Author

Rask Kragh Jørgensen, Rasmus, Bergström, Fanny, Eloranta, Sandra, Tang Severinsen, Marianne, Bjøro Smeland, Knut, Fosså, Alexander, Haaber Christensen, Jacob, Hutchings, Martin, Bo Dahl-Sørensen, Rasmus, Kamper, Peter, Glimelius, Ingrid, E Smedby, Karin, K Parsons, Susan, Mae Rodday, Angie, J Maurer, Matthew, M Evens, Andrew, C El-Galaly, Tarec, Hjort Jakobsen, Lasse, Rask Kragh Jørgensen, Rasmus, Bergström, Fanny, Eloranta, Sandra, Tang Severinsen, Marianne, Bjøro Smeland, Knut, Fosså, Alexander, Haaber Christensen, Jacob, Hutchings, Martin, Bo Dahl-Sørensen, Rasmus, Kamper, Peter, Glimelius, Ingrid, E Smedby, Karin, K Parsons, Susan, Mae Rodday, Angie, J Maurer, Matthew, M Evens, Andrew, C El-Galaly, Tarec, and Hjort Jakobsen, Lasse

Abstract

Purpose Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). Patients and Methods This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort). Results In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis. Conclusion The new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-H, PURPOSE: Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). PATIENTS AND METHODS: This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort). RESULTS: In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis. CONCLUSION: The new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.

Published
2024

14. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy

Author

Crombie, Jennifer L., primary, Graff, Tara, additional, Falchi, Lorenzo, additional, Karimi, Yasmin H., additional, Bannerji, Rajat, additional, Nastoupil, Loretta J, additional, Thieblemont, Catherine, additional, Ursu, Renata, additional, Bartlett, Nancy L., additional, Nachar, Victoria R, additional, Weiss, Jonathan, additional, Osterson, Jane, additional, Patel, Krish, additional, Brody, Joshua D., additional, Abramson, Jeremy S, additional, Lunning, Matthew A, additional, Shah, Nirav N., additional, Ayed, Ayed, additional, Kamdar, Manali, additional, Parsons, Benjamin M., additional, Caimi, Paolo, additional, Flynn, Ian W., additional, Herrera, Alex F., additional, Sharman, Jeff P., additional, McKenna, Marshall, additional, Armand, Philippe, additional, Kahl, Brad S., additional, Smith, Sonali M, additional, Zelenetz, Andrew D, additional, Budde, Lihua E, additional, Hutchings, Martin, additional, Phillips, Tycel J., additional, and Dickinson, Michael, additional

Published
2024
Full Text
View/download PDF

15. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Author

Federico, Massimo, Fortpied, Catherine, Stepanishyna, Yana, Gotti, Manuel, van der Maazen, Richard, Cristinelli, Caterina, Re, Alessandro, Plattel, Wouter, Lazarovici, Julien, Merli, Francesco, Specht, Lena, Schiano de Colella, Jean-Marc, Hutchings, Martin, Versari, Annibale, Edeline, Véronique, Stamatoulas, Aspasia, Girinsky, Theodore, Ricardi, Umberto, Aleman, Berthe, and Meulemans, Bart

Published
2024
Full Text
View/download PDF

16. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Author

Thieblemont, Catherine, Karimi, Yasmin H., Ghesquieres, Herve, Cheah, Chan Y., Clausen, Michael Roost, Cunningham, David, Jurczak, Wojciech, Do, Young Rok, Gasiorowski, Robin, Lewis, David John, Kim, Tae Min, van der Poel, Marjolein, Poon, Michelle Limei, Feldman, Tatyana, Linton, Kim M., Sureda, Anna, Hutchings, Martin, Dinh, Minh H., Kilavuz, Nurgul, Soong, David, Mark, Thomas, Sacchi, Mariana, Phillips, Tycel, and Lugtenburg, Pieternella J.

Abstract

Primary results (median follow-up, 10.7 months) from the pivotal EPCORE®NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. We report long-term efficacy and safety results in patients with LBCL (N= 157; 25.1-month median follow-up). As of April 21, 2023, overall response rate was 63.1% and complete response (CR) rate was 40.1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively. An estimated 64.2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65.1% and 78.2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45.4% had MRD negativity, which correlated with longer PFS and OS. CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index ≥3. The most common treatment-emergent adverse events were cytokine release syndrome (51.0%), pyrexia (24.8%), fatigue (24.2%), and neutropenia (23.6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials.gov Registration: NCT03625037).

Published
2024
Full Text
View/download PDF

17. ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Author

Hutchings, Martin, Carlo-Stella, Carmelo, Morschhauser, Franck, Falchi, Lorenzo, Bachy, Emmanuel, Cartron, Guillaume, Khan, Cyrus, Tani, Monica, Martinez-Lopez, Joaquin, Bartlett, Nancy L., Salar, Antonio, Brody, Joshua, Leppä, Sirpa, Baumlin, Pauline, Mulvihill, Estefania, Relf, James, Xie, Yuying, Kaufman, Derrick, Lundberg, Linda, and Dickinson, Michael

Published
2024
Full Text
View/download PDF

18. ABCL-191 Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Author

Karimi, Yasmin H., Thieblemont, Catherine, Ghesquieres, Herve, Cheah, Chan Y., Roost Clausen, Michael, Cunningham, David, Jurczak, Wojciech, Linton, Kim M., Hutchings, Martin, Phillips, Tycel, Farooq, Umar, Seog Kim, Won, Dinh, Minh H., Ghosh, Jagannath, Pallai, Rajash, Wielgos-Bonvallet, Monica, Eskelund, Christian, Lugtenburg, Pieternella J., and Vose, Julie M.

Published
2024
Full Text
View/download PDF

19. Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Author

Hutchings, Martin, Carlo-Stella, Carmelo, Morschhauser, Franck, Falchi, Lorenzo, Bachy, Emmanuel, Cartron, Guillaume, Khan, Cyrus, Tani, Monica, Martinez-Lopez, Joaquin, Bartlett, Nancy L., Salar, Antonio, Brody, Joshua, Leppä, Sirpa, Baumlin, Pauline, Mulvihill, Estefania, Relf, James, Xie, Yuying, Kaufman, Derrick, Lundberg, Linda, and Dickinson, Michael

Published
2024
Full Text
View/download PDF

20. Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Author

Karimi, Yasmin H., Thieblemont, Catherine, Ghesquieres, Herve, Cheah, Chan Y., Roost Clausen, Michael, Cunningham, David, Jurczak, Wojciech, Linton, Kim M., Hutchings, Martin, Phillips, Tycel, Farooq, Umar, Seog Kim, Won, Dinh, Minh H., Ghosh, Jagannath, Pallai, Rajash, Wielgos-Bonvallet, Monica, Eskelund, Christian, Lugtenburg, Pieternella J., and Vose, Julie M.

Published
2024
Full Text
View/download PDF

21. Long‐term cause‐specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens—A nationwide Danish cohort study.

Author

Rossetti, Sára, Juul, Sidsel Jacobsen, Eriksson, Frank, Warming, Peder Emil, Glinge, Charlotte, El‐Galaly, Tarec Christoffer, Haaber Christensen, Jacob, Kamper, Peter, Nully Brown, Peter, Gislason, Gunnar Hilmar, Vestmø Maraldo, Maja, Tfelt‐Hansen, Jacob, and Hutchings, Martin

Abstract

Summary The documented treatment‐induced excess mortality in Hodgkin lymphoma (HL) has spurred important treatment changes over recent decades. This study aimed to examine mortality among young HL patients treated with contemporary strategies, including historical data comparison. This nationwide study included 1348 HL patients, diagnosed in 1995–2015 and aged 15–40 at diagnosis. Among the patients, 66.5% had Ann Arbor stage I–II and 33.5% had stage III–IV disease. With a median follow‐up of 14.76 years, 139 deaths occurred, yielding a 5‐year overall survival of 94.6%. Older age, advanced disease, earlier treatment periods and extensive regimens were associated with higher overall mortality risk. The cumulative risk of HL‐related death showed an initial sharp rise, with a plateau at 5.3% 10‐year post‐diagnosis. Deaths due to cardiovascular or pulmonary diseases and second cancers initially had minimal risk, gradually reaching 1.2% and 2.0% at the 20‐year mark respectively. HL cases had a 7.5‐fold higher mortality hazard than the background population. This study suggests that contemporary HL treatment still poses excess mortality risk, but recent changes have notably reduced overall and cause‐specific mortality compared to earlier eras. Balancing treatment efficacy and toxicity remains crucial, but our findings highlight improved outcomes with modern treatment approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results